Terms: = Kidney tumors AND FH, HLRCC, 2271, ENSG00000091483, MCUL1, MCL, LRCC, P07954 AND Prognosis
54 results:
1. Humoral complementomics - exploration of noninvasive complement biomarkers as predictors of renal cancer progression.
Revel M; Rezola Artero M; Hamidi H; Grunenwald A; Blasco L; Vano YA; Marie Oudard S; Sanchez-Salas R; Macek P; Rodriguez Sanchez L; Cathelineau X; Vedié B; Sautes-Fridman C; Herman Fridman W; Roumenina LT; Dragon-Durey MA
Oncoimmunology; 2024; 13(1):2328433. PubMed ID: 38487624
[TBL] [Abstract] [Full Text] [Related]
2. Pancreatic Metastasectomy for Secondary Malignancy of the Pancreas: A Single-institution Experience.
Lee O; Yoon SK; Yoon SJ; Kim H; Han IW; Heo JS; Shin SH
Anticancer Res; 2024 Feb; 44(2):703-710. PubMed ID: 38307567
[TBL] [Abstract] [Full Text] [Related]
3. Comparative analyses of tumour immune microenvironment between collecting duct carcinoma and fumarate hydratase-deficient renal cell carcinoma.
Kiyozawa D; Kohashi K; Takamatsu D; Umekita S; Eto M; Kinjo M; Nishiyama K; Taguchi K; Oshiro Y; Kuboyama Y; Oda Y
J Clin Pathol; 2024 Jan; 77(2):105-110. PubMed ID: 36347592
[TBL] [Abstract] [Full Text] [Related]
4. [Consensus on clinical diagnosis and treatment of fumarate hydratase-deficient renal cell carcinoma].
Rare Kidney Cancer Collaborative Group, Genitourinary Cancer Committee, China Anti-Cancer Association
Zhonghua Wai Ke Za Zhi; 2022 Nov; 60(11):961-968. PubMed ID: 36323576
[TBL] [Abstract] [Full Text] [Related]
5. GATA3 aids in distinguishing fumarate hydratase-deficient renal cell carcinoma from papillary renal cell carcinoma.
Liu Y; Dong Y; Gu Y; Xu H; Fan Y; Li X; Dong L; Zhou L; Yang X; Wang C
Ann Diagn Pathol; 2022 Oct; 60():152007. PubMed ID: 35841867
[TBL] [Abstract] [Full Text] [Related]
6. Modified cancer TNM classification for localized renal cell carcinoma based on the prognostic analysis of 3748 cases from a single center.
Zhang J; Li X; Lin J; Liu Z; Tian Y; Wang Q
Can J Physiol Pharmacol; 2022 Jan; 100(1):5-11. PubMed ID: 34779659
[TBL] [Abstract] [Full Text] [Related]
7. Low-grade Oncocytic Fumarate Hydratase-deficient Renal Cell Carcinoma: An Update on Biologic Potential, Morphologic Spectrum, and Differential Diagnosis With Other Low-grade Oncocytic tumors.
Hamza A; Sirohi D; Smith SC; Amin MB
Adv Anat Pathol; 2021 Nov; 28(6):396-407. PubMed ID: 34561376
[TBL] [Abstract] [Full Text] [Related]
8. [Clinicopathological features and prognosis of fumarate hydratase deficient renal cell carcinoma].
Yu YF; He SM; Wu YC; Xiong SW; Shen Q; Li YY; Yang F; He Q; Li XS
Beijing Da Xue Xue Bao Yi Xue Ban; 2021 Aug; 53(4):640-646. PubMed ID: 34393221
[TBL] [Abstract] [Full Text] [Related]
9. A Case of Metastatic Fumarate Hydratase-Deficient-like Renal Cell Carcinoma Successfully Managed by Ipilimumab plus Nivolumab.
Sekito T; Takamoto A; Kobayashi Y; Mitsui M; Watari S; Kubota R; Sadahira T; Iwata T; Nishimura S; Edamura K; Sako T; Araki M; Watanabe M; Watanabe T; Shibata R; Ennishi D; Nasu Y
Acta Med Okayama; 2021 Jun; 75(3):397-402. PubMed ID: 34176946
[TBL] [Abstract] [Full Text] [Related]
10. New developments in existing WHO entities and evolving molecular concepts: The Genitourinary Pathology Society (GUPS) update on renal neoplasia.
Trpkov K; Hes O; Williamson SR; Adeniran AJ; Agaimy A; Alaghehbandan R; Amin MB; Argani P; Chen YB; Cheng L; Epstein JI; Cheville JC; Comperat E; da Cunha IW; Gordetsky JB; Gupta S; He H; Hirsch MS; Humphrey PA; Kapur P; Kojima F; Lopez JI; Maclean F; Magi-Galluzzi C; McKenney JK; Mehra R; Menon S; Netto GJ; Przybycin CG; Rao P; Rao Q; Reuter VE; Saleeb RM; Shah RB; Smith SC; Tickoo S; Tretiakova MS; True L; Verkarre V; Wobker SE; Zhou M; Gill AJ
Mod Pathol; 2021 Jul; 34(7):1392-1424. PubMed ID: 33664427
[TBL] [Abstract] [Full Text] [Related]
11. Clinical characteristics and treatments of hereditary leiomyomatosis renal cell carcinoma: two case reports and literature review.
Feng D; Wang M; Zhang X; Wang J
Aktuelle Urol; 2021 Feb; 52(1):58-63. PubMed ID: 32932527
[TBL] [Abstract] [Full Text] [Related]
12. The prognosis of prechemotherapy blastemal predominant histology subtype in Wilms tumor: A retrospective study in China.
Huang J; Zhang Y; Zhen Z; Lu S; Zhu J; Wang J; Sun F; Liu Z; Gao Y; Li H; Zhang Y; Sun X
Pediatr Blood Cancer; 2020 Nov; 67(11):e28567. PubMed ID: 32813315
[TBL] [Abstract] [Full Text] [Related]
13. Ancestry-specific predisposing germline variants in cancer.
Oak N; Cherniack AD; Mashl RJ; ; Hirsch FR; Ding L; Beroukhim R; Gümüş ZH; Plon SE; Huang KL
Genome Med; 2020 May; 12(1):51. PubMed ID: 32471518
[TBL] [Abstract] [Full Text] [Related]
14. Complement factor H-deficient mice develop spontaneous hepatic tumors.
Laskowski J; Renner B; Pickering MC; Serkova NJ; Smith-Jones PM; Clambey ET; Nemenoff RA; Thurman JM
J Clin Invest; 2020 Aug; 130(8):4039-4054. PubMed ID: 32369457
[TBL] [Abstract] [Full Text] [Related]
15. Hereditary Leiomyomatosis and Renal Cell Cancer: Clinical, Molecular, and Screening Features in a Cohort of 185 Affected Individuals.
Forde C; Lim DHK; Alwan Y; Burghel G; Butland L; Cleaver R; Dixit A; Evans DG; Hanson H; Lalloo F; Oliveira P; Vialard L; Wallis Y; Maher ER; Woodward ER
Eur Urol Oncol; 2020 Dec; 3(6):764-772. PubMed ID: 31831373
[TBL] [Abstract] [Full Text] [Related]
16. A Clinicopathologic and Molecular Analysis of Fumarate Hydratase-deficient Renal Cell Carcinoma in 32 Patients.
Lau HD; Chan E; Fan AC; Kunder CA; Williamson SR; Zhou M; Idrees MT; Maclean FM; Gill AJ; Kao CS
Am J Surg Pathol; 2020 Jan; 44(1):98-110. PubMed ID: 31524643
[TBL] [Abstract] [Full Text] [Related]
17. Fumaratehydratase-deficient renal cell carcinoma: a clinicopathological and molecular study of 13 cases.
Pan X; Zhang M; Yao J; Zeng H; Nie L; Gong J; Chen X; Xu M; Zhou Q; Chen N
J Clin Pathol; 2019 Nov; 72(11):748-754. PubMed ID: 31262952
[TBL] [Abstract] [Full Text] [Related]
18. Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome-Associated Renal Cell Carcinoma Showing High FDG Uptake.
Xiao Z; Dong A; Wang Y
Clin Nucl Med; 2019 May; 44(5):420-423. PubMed ID: 30762823
[TBL] [Abstract] [Full Text] [Related]
19. [Clinicopathological characteristics of fumarate hydratase-deficient renal cell carcinoma].
Zhang W; Chu J; Zou YW; Jiang YX; Wei ZM; Zhong DC; Liu Y; Li YJ; Yu WJ
Zhonghua Bing Li Xue Za Zhi; 2019 Feb; 48(2):120-126. PubMed ID: 30695864
[No Abstract] [Full Text] [Related]
20. Clinical features, treatment, and outcomes of bilateral Wilms' tumor: A systematic review and meta-analysis.
Han Q; Li K; Dong K; Xiao X; Yao W; Liu G
J Pediatr Surg; 2018 Dec; 53(12):2465-2469. PubMed ID: 30274708
[TBL] [Abstract] [Full Text] [Related]
[Next]
